Navigation Links
Aeras and China National Biotech Group Sign Memorandum of Understanding for TB Vaccine R&D Collaboration
Date:7/25/2011

ROCKVILLE, Md. and BEIJING, July 26, 2011 /PRNewswire-USNewswire/ -- Aeras and the China National Biotech Group (CNBG) today announced the signing of a memorandum of understanding for the organizations to pursue opportunities to jointly develop tuberculosis (TB) vaccines in China and potentially other parts of the world.

The partnership is intended to leverage both organizations' capabilities to support the development of TB vaccines.  TB is a major public health priority in China, where there are more than one million new TB cases every year.  The scope of potential activities will cover the full spectrum of product development, including pre-clinical development, process development and manufacturing, and clinical development in TB and potentially other disease areas.  Details of the specific activities and areas of focus of the collaboration will be set forth in a future definitive agreement.

"Aeras is excited to expand our relationship with CNBG," said Jim Connolly, President & Chief Executive Officer of Aeras. "The synergy created by bringing together CNBG's considerable infrastructure and manufacturing expertise with Aeras' promising TB vaccine pipeline, as well as our clinical and technical expertise, will significantly enhance the likelihood of a new TB vaccine being developed quickly and efficiently."

"At CNBG, we recognize the urgent need to combat tuberculosis and other infectious diseases in both China and around the world," said Xiaoming Yang, President of CNBG.  "This new collaboration will bring more opportunities to both organizations in pursuing greater innovation and building increased technical capacity for vaccine development."

The global TB epidemic is responsible for the deaths of 1.7 million people annually.  Co-infection with HIV/AIDS and the spread of drug-resistant forms of TB make it difficult to diagnose and treat, especially in poor and marginalized communities.  New tools to prevent TB, including vaccines, are urgently needed.

About Aeras

Aeras (www.aeras.org) is a non-profit product development organization dedicated to the development of effective TB vaccines and biologics to prevent TB across all age groups in an affordable and sustainable manner.  Aeras utilizes its broad capabilities and technologies in collaboration with numerous partners and stakeholders to support the development of vaccines and other biopharmaceuticals to address TB and other significant public health needs of underserved populations.  Aeras has invented or supported the development of six TB vaccine candidates to date, five of which are currently undergoing Phase I and Phase II clinical testing in Africa, Asia and North America.  Aeras receives funding from private foundations and governments.  Aeras is based in Rockville, Maryland, USA – where it operates a state-of-the-art manufacturing and laboratory facility – and Cape Town, South Africa.

About CNBG

CNBG (www.cnbg.com.cn) is a state-owned enterprise belonging to China's National Pharmaceutical Corporation (Sinopharm).  CNBG has 11 subsidiaries and is the largest biotech corporation in China engaged in the research and development, manufacturing and marketing of biological products. CNBG manufactures more than 200 kinds of biological products (with approximately 100 GMP product lines) for prophylactic, therapeutic and diagnostic use, including all the vaccines in China's EPI programme, and maintains an 80% share of the public sector in China. In 2010, the annual output of CNBG reached 730 million doses, and it maintains one of the broadest portfolios of vaccine products in the world.


'/>"/>
SOURCE Aeras
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
2. Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO
3. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
4. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
5. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
6. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
7. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
8. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
9. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
10. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
11. China Animal Welfare Law Under Review While 36,000 Dogs Culled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):